logo

MRKR

Marker Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.03 / 10
Netural

MRKR's fundamental profile is average (4.0/10). Key positives include strong revenue and profit valuation metrics (Revenue-MV and Profit-MV both score 1), indicating favorable market perception relative to peers. However, concerns linger over the Current assets turnover ratio and Net profit / Total profit percentage, which score 0, suggesting inefficiencies in current asset utilization and potential profitability compression. Overall, the fundamentals call for a cautious approach.

Fundamental(4.03)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.76
Score2/3
Weight17.86%
1M Return11.69%
Inventory turnover ratio
Value47.85
Score3/3
Weight6.88%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score3/3
Weight15.73%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight11.72%
1M Return7.79%
PB-ROE
Value-0.61
Score1/3
Weight10.82%
1M Return7.02%
Current assets turnover ratio
Value0.11
Score0/3
Weight-2.14%
1M Return-1.88%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.00%
1M Return0.86%
Asset-MV
Value-0.50
Score2/3
Weight26.74%
1M Return15.13%
Cash-MV
Value-0.07
Score2/3
Weight11.74%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.35%
1M Return-0.30%
Is MRKR fundamentally strong?
  • MRKR scores 4.03/10 on fundamentals and holds a Fair valuation at present. Backed by its -56.62% ROE, -304.54% net margin, -1.92 P/E ratio, 1.50 P/B ratio, and -7.34% earnings growth, these metrics solidify its Netural investment rating.